Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”This weekend I attended the 2026 Thrombosis and Hemostasis Summit of North America alongside many dedicated colleagues from our Rare Disease team.
I left feeling inspired by the collaboration and expertise that went into making this meeting such a valuable experience.
It was energizing to connect with the thrombosis and hemostasis community, sharing scientific perspectives and how we’re working to shape the future of care for people living with hemophilia.
From scientific presentations to educational symposia, our presence reflected a continued focus on innovation and progress for the rare bleeding disorders community.
THSNA reinforced the power of fueling conversations, sharing insights, and learning together matters as we work to accelerate progress in this area of unmet need.”
Stay updated with Hemostasis Today.
-
May 6, 2026, 14:58Insights on Acquired Hemophilia from ‘Bobby’ Duc Tran – Hemophilia of Georgia
-
May 6, 2026, 14:57Amanda S.: Strengthening the Global Network of Psychosocial Professionals in Bleeding Disorders at WFH 2026
-
May 6, 2026, 14:56Sierra Akers: Discussing the importance of Hemophilia Treatment Centers
-
May 6, 2026, 14:52Christy Abele: Helping People Craft Stories That Connect and Resonate at CHB Symposium
-
May 6, 2026, 14:46Joe Dawson: Follow-Up on a Patient with a History of an IVC Thrombus
-
May 6, 2026, 14:20Emmanuel J. Favaloro: Highlights of Global Haemostasis Testing in the Latest Issue
-
May 6, 2026, 14:02Abdul Mannan: Anemia in Myelofybrosis – Five Fires Behind One Falling Hb
-
May 6, 2026, 14:00Mona Alfaraj: Advancing Care in Inherited Platelet Disorders at 2nd International Hematology and Hemostasis Conference
-
May 6, 2026, 13:56Mahesan Subramaniam: Why Delayed Cord Clamping Benefits Newborn Health